The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 360:2240-2242 May 21, 2009 Number 21
NextNext

Antiplatelet Therapy and Vascular-Access Patency
Charmaine E. Lok, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by Dixon, B. S.
-PubMed Citation
Current predictions estimate that by the year 2020, more than 750,000 people in the United States alone will have end-stage renal disease and over 500,000 will require hemodialysis.1 The success of hemodialysis depends on a well-functioning vascular access, which may be considered the patient's lifeline. However, creating and maintaining a vascular access are challenging and costly. In the first year of hemodialysis, care of the vascular access represents the leading cause of hospitalizations; overall costs are over $1 billion annually.2,3

The Dialysis Access Consortium (DAC) Study Group has taken the lead in advancing clinical knowledge of dialysis access dysfunction and . . . [Full Text of this Article]


Source Information

From the Department of Medicine, Division of Nephrology, Toronto General Hospital, and the University of Toronto — both in Toronto.




HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.